Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some mechanistic and liver/alcohol cautions are partially supported by the provided label excerpts (e.g., statins’ liver enzyme abnormalities and caution with substantial alcohol; increased risk of myopathy/rhabdomyolysis with interacting drugs). However, multiple claims (atherosclerosis prevention, heart disease/stroke risk reduction, alcohol-related liver damage severity/irreversibility, specific outcomes like kidney failure/death, and cognitive impairment) are not supported by the provided label text and several are speculative beyond it.
Category Scores
Accurate Statements
Lipitor (atorvastatin) lowers cholesterol levels in the blood by inhibiting cholesterol production in the liver.
12.1 Mechanism of Action: LIPITOR is a selective competitive inhibitor of HMG-CoA reductase (converts to mevalonate/precursor of sterols including cholesterol) and in animal models lowers plasma cholesterol by inhibiting HMG-CoA reductase/cholesterol synthesis in the liver.
Combining alcohol with Lipitor can increase the risk of adverse effects.
5.2 Liver Dysfunction: LIPITOR should be used with caution in patients who consume substantial quantities of alcohol and/or have a history of liver disease (supports increased risk/need for caution with alcohol).
Alcohol and Lipitor can put additional strain on the liver when consumed together.
5.2 Liver Dysfunction: Statins associated with biochemical abnormalities of liver function; and caution with substantial alcohol use and/or history of liver disease.
Combining alcohol with Lipitor can lead to liver damage or exacerbate existing liver conditions.
5.2 Liver Dysfunction: Active liver disease or unexplained persistent transaminase elevations are contraindications; and caution in patients who consume substantial quantities of alcohol and/or have a history of liver disease.
Combining alcohol with Lipitor may increase the risk of interactions with other medications.
17 Patient Counseling Information: Patients should be advised about substances they should not take concomitantly with atorvastatin (general interaction counseling).
Lipitor can cause muscle damage known as rhabdomyolysis even in healthy individuals.
5.1 Skeletal Muscle: Rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with LIPITOR and with other drugs in this class.
Combining alcohol with Lipitor may increase the risk of rhabdomyolysis.
Not directly supported in provided excerpts. Closest related support is general rhabdomyolysis risk statements in 5.1 and interaction-driven increased risk with specific drugs; however alcohol-specific increase is not stated.
Unsupported Statements
Lipitor helps prevent buildup of plaque in the arteries.
No claim in provided excerpts that LIPITOR prevents plaque buildup; only mechanistic association with atherosclerosis risk factors (12.1) is described.
Lipitor reduces the risk of heart disease and stroke.
No provided excerpt states reduction of heart disease/stroke risk; 1 INDICATIONS AND USAGE provided is limited to being an adjunct for individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia, without explicit heart disease/stroke outcome claims.
Combining alcohol with Lipitor can lead to liver damage or exacerbate existing liver conditions.
Partially supported for caution in substantial alcohol and history of liver disease (5.2), but the wording implies alcohol-driven liver damage/exacerbation; the excerpt does not specifically state alcohol causes liver damage with atorvastatin or that it will exacerbate conditions.
Liver damage from combining alcohol with Lipitor can be irreversible.
The provided label excerpt does not state irreversibility.
Combining alcohol with Lipitor may increase the risk of rhabdomyolysis.
The provided excerpts do not mention alcohol as a factor increasing rhabdomyolysis risk; increased risk is described with certain concomitant interacting drugs (5.1, 7).
Rhabdomyolysis from combining alcohol with Lipitor can cause kidney failure.
The excerpt states rhabdomyolysis with acute renal failure secondary to myoglobinuria has been reported (5.1), but it does not link this outcome to alcohol specifically.
Combining alcohol with Lipitor can increase the risk of interactions with other medications.
The label excerpt does not state alcohol increases risk of drug interactions with atorvastatin. It only provides interaction risk for specific concomitant medications.
Examples of other medications that may interact with Lipitor when combined with alcohol include blood thinners, diabetes medications, and certain antibiotics.
Table 1/7 provided only lists interacting agents relevant to increased risk of myopathy/rhabdomyolysis (e.g., cyclosporine, clarithromycin, itraconazole, HIV protease inhibitors). The specific categories (blood thinners, diabetes medications) and the linkage to alcohol are not supported.
Serious adverse effects from combining alcohol with Lipitor and other medications can include bleeding.
No bleeding outcome is mentioned in provided excerpts.
Serious adverse effects from combining alcohol with Lipitor and other medications can include kidney damage.
Kidney failure is mentioned only in context of rhabdomyolysis with acute renal failure (5.1) but not as a general 'kidney damage' outcome tied to combining alcohol with other medications.
Serious adverse effects from combining alcohol with Lipitor and other medications can include death.
No death outcome is stated in provided excerpts.
Combining alcohol with Lipitor may increase the risk of cognitive impairment.
Provided excerpts do not describe cognitive impairment, and 5.4 focuses on CNS toxicity findings in animals rather than cognitive impairment in humans.
Cognitive impairment associated with combining alcohol and Lipitor can include memory loss and confusion.
No such human cognitive symptoms are stated in provided excerpts.
Contradictions
Important Omissions
For statements about alcohol-related liver risk, the provided label excerpt specifies caution for substantial alcohol intake and contraindication for active liver disease/unexplained persistent transaminase elevations, but does not support claims about irreversibility or inevitable liver damage; an accurate alcohol-related risk framing should align to these specifics.
Importance:
Moderate
Rhabdomyolysis/myopathy increased risk is tied in the excerpts to specific concomitant drugs (e.g., cyclosporine, strong CYP3A4 inhibitors) and certain patient risk factors, but the response attributes increased rhabdomyolysis risk to alcohol; aligning to label-identified interacting agents/risk factors is necessary.
Importance:
Moderate
Drug interaction examples should be limited to those actually listed in the provided label (Table 1/7) for increased myopathy/rhabdomyolysis risk; the response instead provides unsupplied categories (blood thinners, diabetes medications).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several unsupported or over-specific claims (alcohol leading to irreversible liver damage; alcohol-linked rhabdomyolysis with kidney failure/death; bleeding and death; cognitive impairment) could mislead risk perception beyond the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Overstated/unsupported outcome claims about alcohol effects (irreversibility, kidney failure/death, bleeding) and cognitive impairment, and unsupplied drug-interaction examples not present in the provided label excerpts.
Suggested Improvement
Restrict claims to label-supported content in the provided excerpts: (1) mechanistic cholesterol lowering via HMG-CoA reductase inhibition; (2) atherosclerosis risk-factor associations without claiming plaque prevention or explicit heart disease/stroke reduction; (3) alcohol: state 'use caution with substantial alcohol intake' and the contraindication for active liver disease/unexplained persistent transaminase elevations; (4) myopathy/rhabdomyolysis: discuss 'rare cases' and increased risk with specific interacting drugs listed (e.g., cyclosporine, clarithromycin, itraconazole, HIV protease inhibitors) rather than alcohol-linked risk; (5) remove claims about cognitive impairment, bleeding, death, and irreversibility unless supported by label text.